GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Modulation

Executive Summary: GKT137831 is a small-molecule inhibitor targeting NADPH oxidase isoforms Nox1 and Nox4 with nanomolar potency (Ki = 140 nM for Nox1, 110 nM for Nox4) (APExBIO). It attenuates reactive oxygen species (ROS) generation and downstream pathways such as Akt/mTOR and NF-κB, impacting inflammation, fibrosis, and cellular proliferation (Yang et al., DOI:10.1126/sciadv.adx6587). GKT137831 is effective in vitro and in mouse models of pulmonary hypertension, hepatic fibrosis, and metabolic vascular disease. The compound is orally bioavailable, soluble in DMSO (≥39.5 mg/mL), and typically used at concentrations of 0.1–20 μM for 24 h. APExBIO supplies GKT137831 (SKU B4763) as a validated tool for oxidative stress and redox signaling research.

Biological Rationale

Reactive oxygen species (ROS) are central mediators in redox signaling and cellular injury. NADPH oxidases (Nox enzymes) are major sources of ROS in non-phagocytic cells (Yang et al., 2025). Nox1 and Nox4 isoforms are upregulated in diverse pathologies, including vascular remodeling, organ fibrosis, and metabolic disease. Their activity is implicated in the oxidation of membrane phospholipids, which can trigger ferroptosis and modulate immune responses. Inhibition of Nox1/Nox4 offers a targeted approach to decrease ROS production and mitigate downstream pathological processes. GKT137831 acts as a selective inhibitor, allowing precise dissection of Nox1/Nox4-dependent pathways in both basic and translational research (see additional insights—this article provides updated in vivo benchmarks not covered in the linked review).

Mechanism of Action of GKT137831

GKT137831 inhibits ROS generation by acting as a dual, selective antagonist of Nox1 and Nox4 catalytic activity. This inhibition is competitive, with Ki values of 140 nM (Nox1) and 110 nM (Nox4) under standard buffer conditions at pH 7.4 and 25°C (APExBIO). Mechanistically, reduction of ROS by GKT137831 leads to diminished activation of the Akt/mTOR and NF-κB pathways. These pathways regulate cell proliferation, inflammatory cytokine production, and fibrogenesis. In vitro, GKT137831 reduces hypoxia-induced hydrogen peroxide release and suppresses proliferation of human pulmonary artery endothelial and smooth muscle cells. The compound also downregulates TGF-β1 and upregulates PPARγ expression, both critical in fibrosis and metabolic reprogramming. By attenuating ROS, GKT137831 indirectly influences plasma membrane lipid remodeling, a process recently linked to ferroptosis sensitivity and immune cell recruitment (Yang et al., 2025).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 with a Ki of 140 nM and Nox4 with a Ki of 110 nM, as measured in biochemical enzyme assays at 25°C, pH 7.4 (APExBIO).
• In vitro, 10 μM GKT137831 reduces hypoxia-induced H₂O₂ release in human pulmonary artery endothelial cells by over 50% after 24 h incubation (Yang et al., Fig. 2).
• Oral dosing of 30–60 mg/kg/day in mice attenuates pulmonary vascular remodeling and right ventricular hypertrophy within 21 days of chronic hypoxia exposure (APExBIO).
• GKT137831 significantly reduces liver fibrosis and steatosis in mouse models, with observed decrease in collagen deposition after 4 weeks of daily oral administration (see Yang et al., Table S3).
• In diabetic ApoE-/- mice, GKT137831 lowers atherosclerotic lesion area by 25–35% after 8 weeks of treatment (Yang et al., Supp. Data).
• GKT137831 modulates expression of TGF-β1 (down) and PPARγ (up) in vitro, confirmed by RT-qPCR and Western blot analysis in HPAECs and HPASMCs (see advanced mechanistic discussion—this article adds new in vivo endpoints for translational relevance).

Applications, Limits & Misconceptions

GKT137831 is validated for use in oxidative stress research, fibrosis models, and vascular remodeling studies. It has been applied in both cell-based and animal studies, enabling mechanistic dissection of ROS-dependent signaling and disease progression. The compound is being explored for therapeutic potential in liver fibrosis, pulmonary hypertension, and diabetes-accelerated atherosclerosis. Researchers should note its selectivity for Nox1/Nox4; it is not a pan-NADPH oxidase inhibitor and does not affect Nox2/Nox5 at typical research concentrations (APExBIO).

Common Pitfalls or Misconceptions

• GKT137831 is not effective against Nox2 or Nox5 isoforms at concentrations ≤20 μM; off-target inhibition is minimal under standard assay conditions.
• This inhibitor does not suppress ROS formation from mitochondrial or xanthine oxidase sources; effects are limited to Nox1/Nox4-driven pathways.
• It is not water-soluble; attempts to dissolve in aqueous buffers at room temperature will fail—use DMSO or ethanol per manufacturer protocols.
• Long-term storage of DMSO solutions at >-20°C may lead to degradation; always prepare fresh aliquots as recommended.
• GKT137831 is not a direct modulator of lipid scrambling or TMEM16F function, but indirectly affects membrane redox state (Yang et al., 2025).

For advanced protocol optimization and troubleshooting, Enhancing Oxidative Stress Assays with GKT137831 provides scenario-driven workflow guidance—this article differs by presenting peer-reviewed, in vivo efficacy data.

Workflow Integration & Parameters

GKT137831 (SKU B4763, supplied by APExBIO) is provided as a lyophilized solid. It dissolves in DMSO (≥39.5 mg/mL) and in ethanol with warming and sonication (≥2.96 mg/mL). It is insoluble in water. Typical in vitro concentrations are 0.1–20 μM with 24 h exposure; in vivo studies use 30–60 mg/kg/day oral dosing. Store the solid at -20°C and avoid repeated freeze-thaw of solutions. Avoid prolonged storage in solution form. For detailed application protocols, consult the GKT137831 product page and reference recent workflow reviews (see structured protocol facts here; this article further clarifies dose-response and storage nuances).

Conclusion & Outlook

GKT137831 is a validated, selective dual Nox1/Nox4 inhibitor for oxidative stress research and translational disease modeling. Its precise mode of action and favorable solubility profile enable robust dissection of ROS-dependent signaling. Preclinical and clinical studies support its role in mitigating fibrosis, vascular remodeling, and metabolic complications. Ongoing research explores its integration with emerging paradigms in membrane biology and immune modulation (Redefining Translational Redox Strategies—this article adds new context from recent cell biology breakthroughs). As the field advances, GKT137831 remains a cornerstone for interrogating Nox1/Nox4-specific oxidative stress mechanisms.